Alejandro González-marín

Maj Institute of Pharmacology

2 papers in the library · 52 citations · publishing 2020

Papers

Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats

Neurotoxicity Research December 18, 2020 Adam Wojtas, Monika Herian, Mateusz Skawski et al. 33 citations

The hallucinogen 25B-NBOMe, which binds strongly to serotonin receptors, increased dopamine, serotonin, and glutamate release in the rat frontal cortex, striatum, and nucleus accumbens. It induced hallucinogenic activity, impaired short-term memory as measured by the novel object recognition test, and reduced locomotor activity in the open field test. In the light/dark box, rats spent more time in the dark zone, suggesting an anxiogenic effect. Scopolamine blocked the memory impairment. Unlike MDMA, 25B-NBOMe showed a subtle genotoxic effect in the comet assay. The changes in neurotransmitter levels may stem from its affinity for the 5-HT2A receptor.

DOI: 10.1007/s12640-020-00297-8 Full text Serotonin Hallucinogen Chemistry Pharmacology +7

Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.

Pharmacological reports : PR December 1, 2020 Monika Herian, Adam Wojtas, Małgorzata Katarzyna Sobocińska et al. 19 citations

The hallucinogenic compound 25I-NBOMe acts through specific serotonin receptors to produce its effects. In rats, blocking the 5-HT2A or 5-HT2C receptors with selective antagonists reduced both the hallucinogenic-like behavior (wet dog shakes) and the release of glutamate, dopamine, and serotonin in the frontal cortex caused by 25I-NBOMe. Blocking the 5-HT1A receptor did not affect the behavior or glutamate release but did decrease dopamine and serotonin release, likely by disinhibiting GABA neurons. These findings indicate that 5-HT2A and 5-HT2C receptors are key mediators of 25I-NBOMe's hallucinogenic activity and its effects on neurotransmitter release in the frontal cortex.

DOI: 10.1007/s43440-020-00181-4 Full text 25i-nbome 5-ht2a/2c/1a receptor antagonists Hallucinogenic activity Neurotransmission